Kalvista Pharmaceuticals, Inc. (NASDAQ: KALV) has appointed Jeb Ledell as its new Chief Operating Officer (COO). Ledell brings over 20 years of leadership and operational experience in the biotechnology industry, having previously held the same role at Aveo Oncology and Enzyvant Therapeutics, among others.
On December 16, 2024, Ledell was granted inducement options to purchase 100,000 shares of the company's common stock as part of his employment agreement. These options will vest over a four-year period, with 1/4th of the total shares vesting on the one-year anniversary of Ledell’s start date, and 1/48th of the total number of shares underlying the options vesting on each monthly anniversary thereafter, subject to his continued service.
Kalvista Pharmaceuticals is focused on developing and delivering oral medicines for people affected by rare diseases with significant unmet needs. Its novel investigational candidate, sebetralstat, for the treatment of hereditary angioedema, is currently under regulatory review by the FDA with a PDUFA goal date of June 17, 2025. The company has also completed marketing authorization applications for sebetralstat to the European Medicines Agency and multiple other countries. The market has reacted to these announcements by moving the company's shares 1.8% to a price of $8.85. For more information, read the company's full 8-K submission here.
